MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Allogene Therapeutics Inc

Abrir

SetorSaúde

1.33 8.13

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.23

Máximo

1.33

Indicadores-chave

By Trading Economics

Rendimento

8.8M

-51M

Margem de lucro

272,450

Funcionários

226

EBITDA

-335K

-57M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+658.06% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

56M

282M

Abertura anterior

-6.8

Fecho anterior

1.33

Sentimento de Notícias

By Acuity

28%

72%

69 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Allogene Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de out. de 2025, 23:30 UTC

Ações em Alta

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 de out. de 2025, 21:21 UTC

Ganhos

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 de out. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 de out. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 de out. de 2025, 23:39 UTC

Conversa de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 de out. de 2025, 23:00 UTC

Conversa de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Scales's JV Buyout Lauded by Bull -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Forex and Fixed Income Roundup: Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de out. de 2025, 21:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 de out. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

2 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de out. de 2025, 20:49 UTC

Aquisições, Fusões, Aquisições de Empresas

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 de out. de 2025, 20:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 de out. de 2025, 19:20 UTC

Conversa de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 de out. de 2025, 19:10 UTC

Conversa de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 de out. de 2025, 19:04 UTC

Conversa de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 de out. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparação entre Pares

Variação de preço

Allogene Therapeutics Inc Previsão

Preço-alvo

By TipRanks

658.06% parte superior

Previsão para 12 meses

Média 9.4 USD  658.06%

Máximo 14 USD

Mínimo 7 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Allogene Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

7

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.18 / 1.69Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

69 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat